Key Genomics identifies multi-gene signatures to predict critical outcomes such as patient-specific drug sensitivity or compound toxicity.

 

To deliver patient-specific diagnostic intelligence

To optimize clinical trials through patient targeting and compound rescue.

To accelerate drug discovery and development.

 

Using COXEN, a novel, validated predictive informatics technology.

 

Published and validated in three cancers: bladder, breast, and ovarian.

 

Lead diagnostic application: bladder cancer, a disease affecting 50,000 Americans annually, and with the highest lifetime treatment costs per patient of all cancers. (K.D. Sievert, et al World J Urol. Jun, 2009.)